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Research Article
Label-free relative quantification of
alpha-2-macroglobulin site-specific
core-fucosylation in pancreatic cancer
by LC-MS/MS
We describe a label-free relative quantification LC-MS/MSmethod for core-fucosylation in
alpha-2-macroglobulin (A2MG) immunoprecipitated from human sera. The method uti-
lizes endoglycosidase F partial deglycosylation to reduce glycosylationmicroheterogeneity,
while retaining the innermost N-acetylglucosamine (GlcNAc) and core fucose. Precursor
ion peak areas of partially deglycosylated peptides were obtained and site-specific core-
fucosylation ratios based on the peak areas of core-fucosylated and nonfucosylated coun-
terparts were calculated and evaluated for assay development. This assay was applied in
a preliminary study of sera samples from normal controls and patients with pancreatic
diseases, including pancreatic cancer and chronic pancreatitis. A2MG fucosylation levels
at sites N396 and N1424 were found to decrease in both chronic pancreatitis and pancre-
atic cancer compared to normal controls. The two sites were identified by two peptides
and their core-fucosylation ratios were found to be internally consistent. This method
provides a platform to quantify fucosylation levels and can be used to study site-specific
core-fucosylation aberrations in other glycoproteins for other diseases.
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1 Introduction
Protein N-glycosylation, where polysaccharides attach to the
Asn in the sequon of Asn-Xxx-Ser/Thr (Xxx is any amino
acid except Pro), is a prevalent PTM. Protein glycosylation
mediates multiple protein and cell functions including pro-
tein folding, signal transduction, immune response, and cell
metastasis [1, 2]. Protein glycosylation usually reflects the
physiological and pathological environment of cells, and its
alterations have been found to be involved in the pathogenesis
of multiple diseases, including cancers [3–6]. Despite its im-
portance in disease diagnostics, an understanding of protein
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glycosylation has lagged behind achievements in genomics
and proteomics, mostly due to the complexity of glycosyla-
tion and the lack of sensitive characterization and quantifi-
cation methods. One protein may have several glycosylation
sites (glycosylation heterogeneity) with multiple possible gly-
cans at each site (glycosylation microheterogeneity). In most
glycosylation studies,N-glycans are released from the peptide
backbone by peptideN-glycosidase F (PNGase F), followed by
separate qualitative and quantitative analysis of glycans [7, 8]
and deglycosylated peptides [9, 10]. This approach provides
aggregate glycosylation information, but cannot identify site-
specific glycosylation patterns. There are relatively few stud-
ies on intact glycopeptides due to low concentration and poor
ionization efficiency [11]. Quantification of glycopeptides is
usually performed with label-free strategies using precursor
ion intensities [12, 13].
Core-fucosylation, wherein fucose attaches to the inner-
most N-acetylglucosamine (GlcNAc) via an -1,6 linkage, is
a subtype of N-glycosylation, which has attracted research
Colour Online: See the article online to view Figs. 1 and 4 in colour.
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interest due to its potential as a cancer biomarker [6, 14, 15].
Notably, the core-fucosylation level of alpha-fetoprotein (AFP-
L3) is an FDA-approved diagnostic tool for liver cancer [16].
To target site-specific core-fucosylation, endoglycosidase F3
(Endo F3) was used to partially deglycosylate the glycopep-
tides and retain only the core GlcNAc and fucose. This has
been used qualitatively to identify glycosylation sites on both
individual proteins [17] and complex protein mixtures such
as human plasma [18–21]. Quantitative analysis of serum
protein core-fucosylation level changes as a potential hepato-
cellular carcinomamarker has been performed using precur-
sor intensity-based quantification with differential dimethy-
lation [22].
Alpha-2-macroglobulin (A2MG) is one of the most abun-
dant proteins in human serum. It is a tetramer with a
total molecular weight of 720 kDa with eight potential
N-glycosylation sites occupied by complex-type N-glycans
with or without core fucose [17, 23]. As a protease inhibitor,
it is reported to inhibit tumor cell proliferation when bind-
ing to low-density lipoprotein receptor-related protein 1 (LRP
1) [24]. The N-glycosylation of A2MG has been chosen as an
initial system to demonstrate our method for the study of fu-
cosylation ratios since it is a relatively high abundance protein
with eight potential fucosylation sites and is efficiently puri-
fied with an available commercial antibody. In this study, we
utilized a label-free LC-MS/MS method to monitor changes
of human A2MG core-fucosylation at specific glycosylation
sites based on precursor ion intensities of Endo F3-treated
glycopeptides. Exploiting the property that partially deglyco-
sylated glycopeptideswith the samepeptide backbone approx-
imately co-elute by reverse phase LC, the core-fucosylation ra-
tio at a particular glycosylation site was calculated by dividing
the peak area of fucosylated peptide by the peak area of its non-
core fucosylated counterpart. This is a relative quantification
method, which eliminates the need for internal standards.
The fucosylation ratios at two sites (N396 and N1424) of hu-
man serum A2MG were calculated from 20 normal controls,
20 pancreatic cancer patients, and 20 chronic pancreatitis pa-
tients. Core-fucosylation ratios were found to be lower in both
chronic pancreatitis and pancreatic cancer samples relative to
normal controls for both sites. This assay could be utilized to
monitor core-fucosylation changes in other proteins to iden-
tify aberrations in protein core-fucosylation in other diseases.
2 Materials and methods
2.1 Serum samples
Sixty human serum samples (20 normal controls, 20 chronic
pancreatitis patients, and 20 pancreatic cancer patients) were
used; demographic information is given in Table 1. All sam-
ples were collected according to internal review board ap-
proved protocols. Sample aliquots were stored in a −80°C
freezer and frozen and thawed only once.
Table 1. Demographic information and cancer stage information
of human serum samples enrolled in this study
Normal Chronic Pancreatic
pancreatitis cancer
Age (years)
<50 5 6 1
51–60 9 7 5
61–70 6 6 7
>71 0 1 7
Gender
Male 8 13 13
Female 12 7 7
Cancer stage
IIA 2
IIB 6
III 6
IV 6
2.2 Sample preparation
The sample preparation was detailed in previous work [17].
Briefly,A2MGwas immunoprecipitated (Abcam,Cambridge,
MA, USA) from 10 L human serum, which was depleted
of IgG. The immunoprecipitation was performed using the
cross-link IP kit of Pierce Scientific (Rockford, IL, USA) ac-
cording to the manufacturer’s instructions. The immuno-
precipitated protein was desalted using a Zeba spin-column
(Pierce Scientific), and buffer-exchanged to 50 mM ammo-
nium bicarbonate. The protein was reduced with 10mMDTT
at 45°C for 30 min, alkylated with 22 mM iodoacetamide
at room temperature for 45 min, and digested with chy-
motrypsin (Promega, Madison, WI, USA) in a 37°C water
bath overnight. The digest was dried down using a SpeedVac
(Thermo Fisher Scientific, San Jose, CA, USA) and reconsti-
tuted in 80% ACN with 2% formic acid. The glycopeptides
were enriched using ZIC-HILIC microtips (Protea, Morgan-
town, WV, USA), where the tip was equilibrated with 80%
ACN with 2% formic acid, followed by sample loading, wash-
ing, and final elution using 2% formic acid in water. The gly-
copeptides were reconstituted in 50 mM sodium acetate and
partially deglycosylated with Endo F3 (QAbio, Palm Desert,
CA, USA) in a 37°C water bath overnight.
2.3 Nano-LC-linear trap quadrupole (LTQ)-MS
analysis of partially deglycosylated peptides
Nano-LC-MS/MS conditionswere described in previouswork
[17]. Gradient separation was performed with a Paradigm
MG4 micropump system (Michrom Biosciences, Auburn,
CA, USA) with a C18 capillary column (75 m id × 10 cm;
5 m particles) at a flow rate of 300 nL/min. Mobile phase A
was 2% ACN with 1% acetic acid in water and mobile
phase B was 5% water with 1% acetic acid in ACN. The
analytical gradient was from 5 to 60% solvent B in 35 min, a
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rise to 95% in 1 min, a hold for 4 min, a drop to 5% B over
0.1 min, and a hold for 30 min.
An ESI-LTQ mass spectrometer (Thermo Fisher Scien-
tific) was used for analysis. The positive ion mode was used
with spray voltage of 2.2 kV and capillary voltage of 45 V.
Following a full scan over the mass range of m/z 400 to
1800, the four most intense precursor ions were selected for
CID MS/MS (35% normalized collision energy), with the
strongest product ion further selected for MS3 fragmenta-
tion. The activation time for both MS/MS and MS3 is 30 ms.
2.4 Quantitative data analysis
Database search was performed using Proteome Discov-
erer (version 1.1, Thermo Fisher) with SEQUEST using
the following search parameters: (i) static modification: car-
bamidomethylation (+57.0 Da, C); (ii) dynamic modifica-
tions: oxidation (+16.0 Da, M), GlcNAc (+203.1 Da, N), or
GlcNAc-fucose (+349.1 Da, N); (iii) missed cleavages: three;
(iv) enzyme specificity: chymotrypsin (F, W, Y, L); (v) pep-
tide ion tolerance (average mass): 1.4 Da; (vi) fragmentation
ion tolerance (average mass): 0.8 Da. The MS1 precursor
mass was used for MS2, and the MS2 precursor mass was
used for MS3. The MS/MS data were searched against Swiss-
Prot Homo sapiens database (Release 2010_10, downloaded
on November 2, 2010).
Identified partially deglycosylated glycopeptides were
quantified using the peak areas from the extracted ion chro-
matogram (XIC). Peak area integration was performed man-
ually using XCalibur Qual Browser (version 2.1) with the
following parameters: (i) precursor peaks were extracted with
a 1 Da (±0.5 Da) mass window; (ii) scan filter was set as
full MS; (iii) boxcar averaging with seven points was enabled;
(iv) peak detection algorithm was Genesis; (v) S/N threshold
was set at 3.
2.5 Statistical analysis of fucosylation ratios
The fucosylation ratio for each glycosylation site was calcu-
lated as:
Fucosylation ratio = AXIC−fucosylated
AXIC−non-core−fucosylated
(1)
where AXIC-fucosylated and AXIC-non-core-fucosylated are the peak areas
of extracted precursor ion chromatograms of core-fucosylated
peptide and non-core-fucosylated peptide with the same
sequence, respectively.
Four fucosylation ratios were obtained for each sample
and log10 transformed. Each transformed ratio was compared
across samples of different disease states using ANOVA with
Prism 5 (GraphPad, La Jolla, CA, USA). Correlation anal-
ysis of core-fucosylation patterns between different peptide
sequences was performed using R.
2.6 Glycan analysis
Glycan analysis was detailed in previous work [6]. Briefly,
peptide N-glycosidase F (PNGase F, New England BioLabs,
Ipswich,MA, USA) was used to cleave theN-glycans from the
purified A2MG, and the glycans were enriched using porous
graphitized carbon tips (Sigma Aldrich, St. Louis, MO, USA).
Glycans were permethylated and subjected to MALDI-QIT-
TOF MS analysis. The MALDI analysis was performed using
sodiated DHB as the matrix (10 mg/mL DHB in ACN/water
(50:50), with 10mMof sodium chloride) at positive ionmode.
3 Results and discussion
We herein describe an endoglycosidase F assisted label-free
LC-MS/MS analysis method to monitor site-specific core-
fucosylation level change in A2MG, with the following steps
as shown in Supporting Information Fig. 1: (i) identification
of the partially deglycosylated peptide m/z’s and retention
times; (ii) peak area integration of the XIC of the partially deg-
lycosylated peptides; (iii) calculation of the core-fucosylation
ratio for each peptide sequence; and (iv) comparison of core-
fucosylation ratios between samples.
3.1 Selection of enzyme for proteolysis
The non-core- and core-fucosylated glycosylation sites were
identified based onMS2 orMS3 as described in previous work
[17]. In short, MS2 of the peptides with only GlcNAc attached
generates fragmentation on the peptide backbone, enabling
sequence and glycosylation site identification.MS2 of the pep-
tides with GlcNAc-Fuc attached is dominated by defucosyla-
tion, hence a further MS3 on the defucosylated fragment is
needed for peptide backbone fragment to achieve sequence
and site identification. Digestion schemes using trypsin, chy-
motrypsin, trypsin/GluC, and LysC/GluC were compared to
find an optimal method for site identification. Chymotrypsin
enabled identification of five glycosylation sites (N396, N410,
N869, N991, and N1424), while trypsin/GluC and LysC/GluC
both provided three sites and only one site was identified for
trypsin (Table 2). Combining all four digestion methods, all
eight potential N-glycosylation sites of A2MG were identi-
fied. It should be noted that sites N869 and N991 were not
observed to have core-fucosylation, suggesting variation in
the patterns of core-fucosylation between sites in A2MG. For
this study, chymotrypsin was selected due to the number of
sites identified.
3.2 Label-free quantitative analysis
The goal is to monitor the relative glycoform ratio
change at each glycosylation site to identify disease-related
glycosylation aberrations. For this comparative purpose,
semiquantification methods, such as the label-free method
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Table 2. Glycosylation sites identified with different proteolysis
enzymes or enzyme combinations
Enzyme Site Sequencea) Peptide mass
(NF/F)b)
Trypsin 55 GCVLLSYLNETVTVSASLESVR 867.7/916.2
Chymotrypsin 991 VLDYLNETQQL 770/NA
DYLNETQQL 664.1/NA
396 SNATTDEHGLVQF 811.4/ 884.6
YSNATTDEHGLVQF 893.0/966.0
410 SINTTNVMGTSL 720.9/794.0
869 AVTPKSLGNVNF 725.7/NA
1424 LDKVSNQTL 611.0/684.0
IYLDKVSNQTL 749.2/822.2
Trypsin/GlucC 247 MNVSVCGLYTYGK 848.2/921.4
396 ANYYSNATTDE 726.3/799.6
869 SLGNVNFTVSAE 721.1/NA
LysC/GluC 396 VIFIRGNEANYYSNATTDE 1189.5/1262.6
70 SVRGNRSLFTDLEAE 633.5/682.2
55 GCVLLSYLNE 685.8/758.8
a) Glycosylation site is labeled as N.
b) F and NF indicate core-fucosylated glycopeptide and
non-core-fucosylated glycopeptide, respectively. NA indicates
that no fucosylated peptide was detected.
based on peak areas of glycopeptide XICs, was considered
appropriate.
While most studies of site-specific glycosylation quan-
tification are performed on intact glycopeptides, the high
heterogeneity, low concentration, and poor ionization effi-
ciency of individual glycopeptides complicates the LC-MS
analysis. Since the glycosylation subtype of interest in this
study is core-fucosylation, exoglycosidases and endoglycosi-
dases could be used to remove secondary features. To quantify
core-fucosylation, endoglycosidase F was used to leave only
core GlcNAc or GlcNAc-Fuc, if there is core-fucosylation, to
significantly reduce glycosylation microheterogeneity. This
approach has three major advantages compared to intact gly-
copeptide analysis: (i) the ionization efficiency of partially
deglycosylated peptides was significantly increased; (ii) the
sensitivity of the assay was improved due to the signal stack-
ing effect; and (iii) data analysis was greatly simplified.
Label-free quantification based on the precursor ion peak
intensity has been used in quantification of both the protein
abundance and protein PTMs, including glycosylation [13].
The peak areas of ten partially deglycosylated peptides (five
pairs, both fucosylated and non-core-fucosylated) from each
of the 60 samples (20 normal control, 20 chronic pancreatitis,
and 20 pancreatic cancer) were extracted. A low-resolution
instrument could be used in this case because of the low
sample complexity due to the effective isolation of a single
protein and purification of glycopeptides. Over 90% of par-
tially deglycosylated peptides quantified were identified by
database searching. The peak areas of the few unidentified
peptides were extracted based on the protein correlation pro-
filing using similarity in both retention time (±1.5 min) and
precursor mass (±0.5 Da), which is made possible due to the
affinity purification of A2MG.
3.3 Core-fucosylation ratio indexes
Fucosylation degree, the relative abundance of fucosylated
glycans in a mixture of oligosaccharides, has been used to
provide a quantitative description of fucosylation changes of
N-glycans in various disease states [6,25]. In this study, core-
fucosylation ratios were obtained for glycopeptides and quan-
tification of site-specific core-fucosylation is reported for the
first time. Prior work has quantified only the core-fucosylated
peptides, but not the non-core-fucosylated counterparts [22].
Hence, it was unclear if changes occurred in the protein
amount or extent of core-fucosylation. The work reported in
this study quantifies the frequency of core-fucosylation with-
out being influenced by the underlying protein amount.
It was found that the core- and non-core-fucosylated pep-
tideswith the samepeptide backbone approximately co-eluted
(Fig. 1) by RPLC probably because the retention behavior was
largely determined by the peptide backbone. Amongfive pairs
of deglycosylated peptides detected, the mean absolute differ-
ences in retention times of the four pairs of peptides (Fig. 1;
labeled 1, 2, 4, and 5) were 6 s, while the mean absolute
difference in retention time for another pair (3) was larger
at 30 s. Due to the relatively large difference in the reten-
tion time, the fucosylation ratios at site 410 (3) were excluded
from further discussion. It is generally believed that appro-
priate normalization either by an internal standard or total
peak area is needed in the LC-MS label-free quantification.
Figure 1. XIC of four pairs of partially deglycosylated peptides.
The figure on the top is the non-core-fucosylated peptide and the
figure on the bottom is the fucosylated counterpart with the same
peptide backbone (RT: retention time, in min; AA: peak area; BP:
base peak m/z).
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However, such need is eliminated in this study because core-
and non-core-fucosylated peptides have similar chromato-
graphic behavior and serve as a reference for each other for
relative ratio construction.
It was recently reported that core fucose in intact gly-
cans is vulnerable to in-source loss, resulting in decrease of
fucosylation ratio [26]. However, we observed that the core
fucose remained stable when the glycan was attached to the
peptides. As described, there was a minor but noticeable re-
tention time difference between the fucosylated and nonfuco-
sylated peptides with the same peptide sequence. If there was
significant in-source fragmentation, nonfucosylated peaks at
both the retention time of nonfucosylated and fucosylated
peptides would have been observed. We did not observe such
peak splitting in our study.
Interday reproducibility by analyzing four aliquots of the
same serum sample were analyzed on different days; a CV
less than 11% (Supporting Information Table 1) was found.
The variation originates from steps including enzymatic di-
gestion, ZIC-HILIC SPE, LC-MS instrumentation, and peak
integration. Chymotrypsin generates a reproducible, but
overlapping, set of peptides due to its moderate specificity
(Table 2). To compare the core-fucosylation degree at a partic-
ular site, all corresponding peptide sequences were included.
Pearson’s r correlation analysis was performed to evaluate the
correlation of core-fucosylation ratios between peptides with
the same glycosylation site (N396 and N1424), respectively,
as shown in Fig. 2, and between peptides corresponding to
different sites (Supporting Information Fig. 1). A Pearson’s
r value between 0.5 and 1 indicates positive correlation. The
core-fucosylation ratios of peptides containing the same gly-
cosylation site were positively correlated (r  0.8), indicating
high internal consistency of the quantification results. With
regards to intersite correlation, fucosylation ratios at N396
and N1424 are also positively correlated, ranging from 0.72
to 0.95 (Supporting Information Fig. 1).
3.4 Statistical analysis
Fucosylation ratios of four pairs of peptides from two glyco-
sylation sites were compared across 60 samples categorized
in the three disease states to generate a 4 × 60 data ma-
trix (Supporting Information Table 2). The fucosylation ra-
tios ranged from 0.1 to 20, revealing high diversity in the
distribution of core-fucosylation. A log10 transformation was
performed to correct the deviation from normality for most
populations (Supporting Information Tables 3–5) except for
the population of chronic pancreatitis with peptide sequence
YSNATTDEHGLVQF (m/z: 893.0/966.0) due to one ex-
tremely low value. This value was considered as an outlier
and was removed (Supporting Information Table 6).
To compare the fucosylation ratio changes between
groups, a one-way ANOVA F-test was applied to compare
the means of three different groups (normal, chronic pancre-
atitis, and pancreatic cancer) and multiple comparisons were
performed with Tukey’s test. Briefly, the null hypothesis of
Figure 2. Correlation analysis of fucosylation ratios between
peptide sequences with the same site. Fucosylation ratios of
peptide sequences corresponding to the same site (site 396:
m/z 811.5/884.5 and m/z 893.0/966.0 in (A) and site 1424: m/z
611.0/684.0 and m/z 749.2/822.2 in (B)) are positively correlated.
the F-test is that the three groups involved in comparison
have the same mean (not statistically different). F-test com-
pares the between-group variance against in-group variance,
and the higher the F-value, the stronger the likelihood to re-
ject the null hypothesis, indicating that the difference in the
means of three groups is statistically significant. In this study,
a p-value (false positive rate) of 5% was used. In conjunction
with F-test, Tukey’s test compares all the pairwise means and
identifies these pairs with mean differences greater than the
standard errors.
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Figure 3. Scatterplots of log fucosylation ratios at four
peptide sequences from two glycosylation sites. Twenty
samples per disease states (normal, chronic pancreati-
tis, and pancreatic cancer) were included in comparison,
except in (B) where only 19 data points are shown in the
pancreatitis group due to removal of an outlier.
In general, a statistically significant fucosylation decrease
was observed in all four pairs of peptides corresponding
to two sites (sites 396 and 1424) of A2MG in pancreatic
diseases (including pancreatic cancer and chronic pancre-
atitis) compared to normal controls, while the pancreatic
cancer and chronic pancreatitis were indistinguishable. Scat-
terplots in Fig. 3 provide a graphical comparison of the trans-
formed fucosylation ratios of the four pairs of peptides, with
the brackets showing the statistically significant comparison
(p-value 0.05). Core-fucosylation decreases in both chronic
pancreatitis and pancreatic cancer at both sites. A decrease
of core-fucosylation was also observed in the global A2MG
N-glycan level where N-glycans were extracted, permethy-
lated, analyzed using MALDI MS, and compared between
normal control, chronic pancreatitis, and pancreatic cancer
as shown in Fig. 4.
The effect sizes were calculated as follows to quantify the
extent of fucosylation decrease:
d = x¯1 − x¯2
S
(2)
where x¯1 and x¯2 are the means of core-fucosylation ra-
tios at a particular peptide sequence for disease groups in-
volved in comparison, and S is the average SD. As shown in
Table 3, A2MG shows a one to two SD decrease in fuco-
sylation ratio in chronic pancreatitis and pancreatic cancer
patients for all the three glycosylation sites studied. A2MG
core-fucosylation ratios of chronic pancreatitis and pancre-
atic cancer decrease to anywhere from 6 to 65% of the normal
control values.
Power analysis was performed to justify the sample size
used in this study (20 samples per disease state). The power
analysis of an ANOVA test involves the following parame-
ters: sample size, power, statistical significance (false posi-
tive rate, which is set at 5%), and the effect size calculated as
below:
f =
√∑3
i=1 pi ∗ (ui − u)2
2
(3)
pi = 1/3,i is themean of group i, is themean of all groups,
and 2 is the variance.
The statistical powers for all four ANOVA tests of core-
fucosylation ratios are higher than 95% as shown in Table 3.
Thus, if we fix the significance level at 5%, with a sample size
of 20 for each disease state, the probability to detect such an
effect size is over 95%. Conversely, we can obtain the number
of samples per group to detect a given effect size at a statistical
power of 90% and significance level of 5%. As illustrated in
Table 3, up to 14 samples per group are required, which
provides the statistical support for the number of samples
included in our study.
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Figure 4. Comparison of A2MG N-glycan profiles between nor-
mal control (top), chronic pancreatitis (middle), and pancreatic
cancer (bottom).
4 Concluding remarks
An endoglycosidase-assisted label-free LC-MS/MS assay for
relative quantification of site-specific core-fucosylation was
developed and applied to human serum A2MG. The strat-
egy described herein was utilized in a preliminary study of
A2MG core-fucosylation changes in pancreatic diseases, in-
cluding pancreatic cancer and chronic pancreatitis, wherein
Table 3. Statistical summary of core-fucosylation ratios in
different disease states
Site 396 Site 396 Site 1424 Site 1424
811.5/884.5 893.0/996.0 611.0/684.0 749.2/822.2
 (normal) 0.232 0.251 0.285 0.250
 (pancreatitis) 0.253 0.242 0.248 0.383
 (cancer) 0.231 0.196 0.237 0.206
 (normal) 0.535 0.448 0.728 0.770
 (pancreatitis) 0.034 0.145 0.286 0.341
 (cancer) 0.154 0.247 0.474 0.284
Effect size (N-CP) 2.069 1.233 1.656 1.354
Effect size (N-C) 1.576 0.922 1.047 1.648
Percentage (CP/N) 6.3% 32.3% 39.3% 44.3%
Percentage (C/N) 28.8% 55.0% 65.1% 37.0%
Power of ANOVA 99.9% 97.5% 99.9% 99.9%
n (power 90%) 6 14 9 7
N stands for normal controls, CP stands for chronic pancreatitis,
PC stands for pancreatic cancer, Percentage CP/N (or PC/N) is
calculated as the mean of core-fucosylation ratios of chronic
pancreatitis (or pancreatic cancer) divided by the mean of
core-fucosylation ratios of normal controls.
core-fucosylation levels were found to be decreased at sites
396 and 1424 in both chronic pancreatitis and pancreatic can-
cer compared to normal controls. Although pancreatic can-
cer cannot be distinguished from chronic pancreatitis in this
study, this described strategy could be effectively applied to
other glycoproteins to monitor the aberration in site-specific
core-fucosylation, which may lead to improved pancreatic
cancer diagnostics by utilizing a panel of proteins.
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